What is CVRX's market cap?

$42.09M, based on the Nov 4 close of $1.58.

Does CVRx pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CVRX is sold short?

2.1M shares, 15.3% of float, as of Oct 15, 2026.

What sector is CVRX in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · CVRXHealthcareSurgical Instruments

CVRx, Inc. Common Stock (CVRX)

$1.58+14.49%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$1.38▼ 86.68% in range

Nov 3, 2025Low $1.30 · High $10.36Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

CVRx closed at $1.58 on Nov 4, up 14.49%, 84.7% below its 52-week closing high. Volume of 368.5K shares was 0.88× its 20-day average (close to normal).

Split-adjusted performance: -2.5% over one month, -77.7% over six months, -84.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $15.71M, up 15.6% from a year earlier, with a net margin of -89.4%.

Short interest was 2.1M shares at the Oct 15 settlement, up 7.8% from the prior report (15.3% of float, 3.1 days to cover).

Market cap$42.1M26.6M shares

Revenue · quarter$15.7M+15.6% YoY

Diluted EPS$-0.53—

P/E · TTM—P/S 0.7×

Net margin-89.4%Gross 87.4%

Dividend yieldNone

52-week range1.30 – 10.36−84.7% from high

Volume368.5K0.88× 20-day avg

Volatility · 60d111.7%Annualised

Short % of float15.3%3.1 days to cover

Net cash$6.0MCash $64.6M

Next earnings—Not scheduled

Split-adjusted performance

1W +12.9%1M −2.5%3M −73.4%6M −77.7%YTD −77.7%1Y −84.7%3Y −87.8%5Y −90.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum9

Revenue growth64

Net margin25

Value (low P/E)—

Size30

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short2.1M+7.8% vs prior

Days to cover3.1Settled Oct 15

% of float15.3%

Short vol. 10d47.5%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CVRXCVRx	$1.58	+14.49%	−77.7%	+15.6%	−89.4%	—	$42.1M
XTNTXtant Medical Holdings	$0.2960	+6.47%	−48.7%	−35.0%	−40.9%	—	$41.5M	Compare
TELATELA Bio	$0.8378	+4.46%	−15.4%	−4.5%	−58.4%	—	$37.8M	Compare
NSPRInspireMD	$0.7810	+18.71%	−32.7%	−0.4%	−808.8%	—	$36.6M	Compare
MDAISpectral AI	$1.53	+2.00%	−31.1%	−30.4%	−118.5%	—	$49.2M	Compare
SNWVSANUWAVE Health	$5.73	−3.37%	−64.0%	−3.1%	−7.0%	3.4	$49.3M	Compare
NEPHNephros	$3.25	+0.31%	+0.9%	+36.2%	19.9%	20.3	$35.3M	Compare
DXRDaxor	$8.91	+2.44%	−12.1%	+2.3%	−403.2%	—	$52.0M	Compare
SRTSSensus Healthcare	$3.25	−1.07%	−20.5%	−68.7%	−382.1%	—	$53.5M	Compare

News about CVRx

All news →

CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover LossesGlobeNewswire Inc. · Aug 10, 2026▼ Negative CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution DisclosuresGlobeNewswire Inc. · Aug 7, 2026▼ Negative CVRx, Inc. Investigated by the Portnoy Law FirmGlobeNewswire Inc. · Apr 9, 2026▼ Negative

Quick answers

What does CVRx do?: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
What is CVRX's market cap?: $42.09M, based on the Nov 4 close of $1.58.
Does CVRx pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CVRX is sold short?: 2.1M shares, 15.3% of float, as of Oct 15, 2026.
What sector is CVRX in?: Healthcare, in the Surgical Instruments industry.

About CVRx

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

HQ: Minneapolis, MN223 employeesListed Jun 30, 2021cvrx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology